Madrigal Pharmaceuticals, Inc.
MDGL
Clasificación en acciones
#1949
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Precio por acción
$469.52
Última sincronización: 2026-10-20
Capitalización bursátil
$10.85B
Cambio (1 día)
5.02%
Cambio (1 año)
9.19%
País
US
Comercio Madrigal Pharmaceuticals, Inc. (MDGL)
Categoría
Healthcare
Ingresos de Madrigal Pharmaceuticals, Inc. (MDGL)
Ingresos en Jun 2026 TTM: $1.28B
Según los últimos informes financieros de Madrigal Pharmaceuticals, Inc., los ingresos actuales de la empresa (TTM) son $1.28B. En 2023, la empresa obtuvo unos ingresos de 0.00 igual a los ingresos del año 2022, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Madrigal Pharmaceuticals, Inc. desde 2001 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.28B | 612.77% |
| 2024 | $180.13M | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | $7.58M | -48.77% |
| 2010 | $14.80M | -89.74% |
| 2009 | $144.25M | 5,416.06% |
| 2008 | $2.62M | 251.95% |
| 2007 | $743.00K | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $173.00K | -86.73% |
| 2003 | $1.30M | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 883.25% |
US
|
|
| $2.23B | 73.53% |
US
|
|
| $15.74B | 1,126.25% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 368.97% |
NL
|
